Merus N.V. (NASDAQ:MRUS) COO Peter B. Silverman Sells 16,805 Shares

Merus N.V. (NASDAQ:MRUS - Get Free Report) COO Peter B. Silverman sold 16,805 shares of the stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $55.00, for a total value of $924,275.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Peter B. Silverman also recently made the following trade(s):

• On Wednesday, July 9th, Peter B. Silverman sold 6,695 shares of Merus stock. The stock was sold at an average price of $55.00, for a total value of $368,225.00.
• On Friday, June 20th, Peter B. Silverman sold 34,000 shares of Merus stock. The stock was sold at an average price of $52.76, for a total value of $1,793,840.00.

Merus Stock Performance

NASDAQ MRUS traded up $1.12 during trading hours on Monday, hitting $55.62. The company had a trading volume of 694,277 shares, compared to its average volume of 732,623. Merus N.V. has a 52 week low of $33.19 and a 52 week high of $62.98. The firm has a 50 day simple moving average of $50.76 and a 200 day simple moving average of $45.66. The firm has a market capitalization of $3.85 billion, a price-to-earnings ratio of -13.63 and a beta of 1.00.

Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). Merus had a negative net margin of 506.73% and a negative return on equity of 35.99%. The firm had revenue of $26.49 million for the quarter, compared to analysts' expectations of $7.82 million. On average, research analysts forecast that Merus N.V. will post -3.85 earnings per share for the current year.

Institutional Investors Weigh In On Merus

Large investors have recently made changes to their positions in the business. Boxer Capital Management LLC bought a new stake in shares of Merus during the fourth quarter valued at approximately $79,895,000. Paradigm Biocapital Advisors LP grew its holdings in Merus by 99.4% during the first quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock valued at $141,831,000 after purchasing an additional 1,679,777 shares during the period. Wellington Management Group LLP grew its holdings in Merus by 34.9% during the first quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company's stock valued at $198,588,000 after purchasing an additional 1,220,519 shares during the period. Avoro Capital Advisors LLC grew its holdings in Merus by 56.8% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company's stock valued at $89,356,000 after purchasing an additional 770,000 shares during the period. Finally, Westfield Capital Management Co. LP grew its holdings in Merus by 51.2% during the first quarter. Westfield Capital Management Co. LP now owns 1,501,220 shares of the biotechnology company's stock valued at $63,186,000 after purchasing an additional 508,063 shares during the period. 96.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

MRUS has been the topic of a number of recent analyst reports. Guggenheim reiterated a "buy" rating and issued a $109.00 target price on shares of Merus in a research report on Friday, March 28th. Wells Fargo & Company decreased their target price on Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Wall Street Zen upgraded Merus from a "sell" rating to a "hold" rating in a research report on Saturday. William Blair reiterated an "outperform" rating on shares of Merus in a research report on Monday, April 28th. Finally, BMO Capital Markets set a $110.00 target price on Merus and gave the company an "outperform" rating in a research report on Friday, May 23rd. One equities research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $84.64.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.